Navigation Links
N30 Pharma Announces Successful Initiation of Human Studies With N30-201
Date:1/28/2008

BOULDER, Colo., Jan. 28 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of respiratory drugs that target endogenous s-nitrosothiols, announced today that it has successfully completed Phase 1 study of N30-201 in healthy volunteers. N30 intends to develop N30-201 for the treatment of reactive and obstructive airway diseases, including Cystic Fibrosis and asthma.

"We are pleased to have begun and completed the first set of human studies of N30-201. We believe that N30-201 could be an important therapy for the treatment of many respiratory diseases. Determining the safety of acute administration of N30-201 to human subjects is the first step," commented Charles Scoggin, M.D., Chairman of N30 Pharma.

The primary endpoint of the study was patient safety and characterization of adverse events, but the company collected pharmacokinetic and pharmacodynamic data of ascending doses of N30-201.

About N30-201

N30-201 is a proprietary nebulized formulation of s-nitrosoglutathione (GSNO), an endogenous bronchodilatory molecule that serves as a crucial store of nitric oxide (NO) bioactivity in the human airway.

About N30 Pharma

N30 Pharma is developing s-nitrosothiol therapies for important unmet needs in respiratory diseases. N30's strategy focuses on administration of GSNO to the human airway, and development of small molecule inhibitors of GSNO reductase. GSNO reductase is the key enzyme in the body that breaks down GSNO. These approaches allow N30 to deliver long lasting, physiologically relevant doses of s-nitrosothiols to target systems. S-nitrosothiols are endogenous molecules that store and transduce nitric oxide, and are critical modulators of airway and vascular smooth muscle tone. N30 is a privately held company headquartered in Boulder, Colorado.


'/>"/>
SOURCE N30 Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
2. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
3. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
4. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
6. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
7. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
8. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
9. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015 Semler Scientific, Inc. (Nasdaq: ... that develops, manufactures and markets products that assist healthcare ... reported financial results for the first quarter ended March ... of 2015, Semler reported continued progress with year over ... revenue growth of 14%," said Doug Murphy-Chutorian , ...
(Date:5/1/2015)...  Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ... the results of the Phase 3 Rocket 1 trail ... failing to meet its end points, compelling data from ... future studies. An analyst report on AERI ... review, analyst summary, valuation, and recommendation can be viewed ...
(Date:4/30/2015)... 30, 2015  Accuray Incorporated (Nasdaq: ARAY ... agreement with MIM Software Inc. to further develop ... and CyberKnife ® product portfolios. The new software ... This is Accuray,s second collaboration with MIM; the ... first iPad-based treatment plan review capability, PlanTouch™. ...
Breaking Medicine Technology:Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3
(Date:5/2/2015)... Kare Visits LLC. launched in Chicago in response to the ... offers relief for caregivers by visiting loved ones in nursing ... the Caregiver Action Network, eight in ten caregivers are employed. ... caring for an elderly or disabled loved one. For ... caregiver is now empowered to schedule an on demand visit ...
(Date:5/2/2015)... 2015 With the success that Veatch Dental ... to welcome Neida Miranda and Alex Shields to the team. ... over 41 years of combined experience working with dentists to ... dental field for 8 years. She was certified as ... Customer service, positive attitude and showing the importance of oral ...
(Date:5/1/2015)... Pioneer Millworks, the largest reclaimed wood company ... reclaimed wood products at the 27th annual International Contemporary ... NYC this May. Their newest offerings, Vat 35, Mushroom ... and color to North America's platform for global design. ... color in the design world and we're excited to ...
(Date:5/1/2015)... May 01, 2015 The Workgroup ... nonprofit authority on the use of health IT to ... key contributing resource to the United States Government Accountability ... electronically readable cards in Medicare. The report, “ Potential ... ” was released to the public on Apr. 24, ...
(Date:5/1/2015)... 2015 Hope For The Warriors® thanks ... For The Warriors® and military families. All American Ford ... For The Warriors®, a national nonprofit dedicated to restoring ... restoring hope for our service members and our military ... Ford collected and matched small autograph fee from fans ...
Breaking Medicine News(10 mins):Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2
... Sept. 11 At a press conference held in Coral Gables ... of the organization,s alliance with Navarro Discount Pharmacies. Centro Mater is ... from six weeks to 12 years of age. The organization ... County - two in Hialeah, two in Little Havana, and one ...
... 11 During its 2009 Annual Conference in Washington, DC from September ... of the most pressing issues facing private care registries in the country ... include: , , , ... The program will cover PCA,s actions in the effort to hold ...
... GREENSBORO, N.C., Sept. 11 Merz Pharmaceuticals, LLC, a ... Food and Drug Administration (FDA) has accepted for review ... , , Belotero(R) Balance is a ... a cohesive polydensified matrix (CPM(TM)) technology. This application seeks ...
... , LOS ANGELES, Sept. 11 ... with singer/songwriter/actress/philanthropist Consuelo Vanderbilt Costin for Ovarian Cancer Awareness Month, ... against ovarian cancer. The campaign,s purpose is to educate ... of this deadly disease, support research and advocate for increased ...
... , LIBERTYVILLE, Ill., Sept. 11 They,re BAA-AACK! ... nationwide, the teeny, insidious bloodsuckers--which feast on sleeping humans--are making a ... being spotted in hotels from coast to coast. And not just ... a recent study of 700 mid-priced hotels, 25% were found to ...
... , , DALLAS, Sept. 11 ... (OTC Bulletin Board: ACCP) has entered into an ... North American distribution. One or more U.S. market seeding studies could ... In a comparison of cancer patients receiving standard oral mucositis ...
Cached Medicine News:Health News:Alliance Between Centro Mater and Navarro Discount Pharmacies 2Health News:Private Care Association to Tackle Major Issues Impacting Home Care Industry 2Health News:Merz Pharmaceuticals' Belotero(R) Balance PMA Filing Formally Accepted for Review by the FDA 2Health News:Ovarian Cancer Coalition Partners With Consuelo Vanderbilt Costin 2Health News:Rest Easy, the Safe, All-Natural Bed Bug Travel Spray 2Health News:Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States 2Health News:Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States 3Health News:Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States 4
... Featuring up to ... allows examination in the ... sections plus the option ... for corneal transillumination., ,Filters ...
... to 20 tilting tower ... the vertical, horizontal and ... option to offset the ... ,Filters include Cobalt blue; ...
... outstanding optical system of the Keeler SL-40H, ... fibre optic illumination system with diffuser added ... camera. The result is an excellent digital ... option of capturing stills or video clips ...
With a high lens and filter range this ophthalmoscope is ideal for the Primary Care Specialist...
Medicine Products: